Form 4: Director Leahy Acquires Pasithea Therapeutics Shares

Pasithea Therapeutics Director Emer Leahy acquired 33,333 shares of common stock at $0.75 per share.

Summary

• Emer Leahy, a Director of Pasithea Therapeutics Corp. (KTTA), acquired 33,333 shares of the company's common stock.
• The transaction occurred on November 28, 2025, with shares purchased at a price of $0.75 per share.
• Following this acquisition, Emer Leahy directly beneficially owns 33,333 shares of Pasithea Therapeutics Corp. common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director is a positive signal, indicating insider confidence. While not a major corporate announcement, it provides a favorable sentiment regarding the company's prospects.

Positives

• A Director's acquisition of company stock signals confidence in the company's future prospects and valuation.
• The purchase of 33,333 shares represents a direct investment by a key insider.

Future Outlook

NA

Industry Context

This transaction is an insider-specific event and does not directly relate to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator, potentially increasing confidence in the stock.

Key Dates

Recommendation

The direct acquisition of common stock by a company director, Emer Leahy, signals strong insider confidence in Pasithea Therapeutics Corp.'s future. Such insider buying is often interpreted by seasoned investors as a positive indicator of potential future performance and undervaluation, suggesting a 'buy' recommendation based on this specific signal.

Keywords

Pasithea Therapeutics, KTTA, Emer Leahy, Insider Trading, Form 4, Stock Acquisition, Director Purchase, Beneficial Ownership